Advancing Cancer Care and expanding the boundaries of Personalized Medicine
Current applications address critical unmet needs in cancer care. Future direction includes expanded therapeutic areas.
Addressing Critical Unmet Needs and Costly Trial-And-Error Approaches
Tumor Cell Testing
Why: Less than 25% of late-stage cancer patients benefit from current approaches
- Direct measurement of drug response - 48-hour rapid turnaround time - Broad validations for true personalization - CLIA-certified laboratory - Enhanced therapy selection
Travera's innovative biophysical platform accurately measures how cancer cells respond to therapies, delivering a 3-4x improvement in response prediction and informing expanded therapeutic options
02
Universal Application
Our technology works across virtually all cancer types and treatment modalities including cytotoxics, targeted inhibitors, and immunotherapies, eliminating the limitations of traditional biomarker approaches. Travera's platform has been validated in solid tumors and hematologic malignancies, demonstrating consistent performance regardless of cancer origin.
03
Rapid and Cost-effective Approach
Results delivered within days, not weeks, enabling faster clinical decision-making when time matters most. Our streamlined workflow eliminates complicated processing steps and expensive sequencing, providing actionable insights at a fraction of the cost of comprehensive genomic profiling.
Market Reaction
“As our patients use the Travera test, the Cancer Commons database will show which drugs and cancer subtypes get the most accurate therapy guidance.”
Marty Tenenbaum
Founder, Cancer Commons
Clinical Evidence
Travera's comprehensive clinical validation program confirms the accuracy, reliability, and clinical utility of this single-cell biophysical platform.
By directly measuring how cancer or immune cells respond to therapies, providing actionable insights that translate to meaningful improvements in patient outcomes. This evidence-based approach ensures physicians can confidently integrate this technology into their clinical decision-making process.
